Uniclophen

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Uniclophen

What is Uniclophen?

Uniclophen is a pharmaceutical formulation containing diclofenac sodium, a compound belonging to the class of medications known as non-steroidal anti-inflammatory drugs (NSAIDs). It is primarily utilized for its analgesic and anti-inflammatory properties, specifically designed for ophthalmic application.

Mechanism of Action

The active ingredient in Uniclophen works by inhibiting the biosynthesis of prostaglandins. Prostaglandins are lipid compounds produced within the body that play a central role in mediating inflammation, pain, and fever. By blocking the enzymes responsible for producing these compounds, the medication helps to reduce swelling and discomfort in the ocular tissues.

Therapeutic Applications

Uniclophen is typically indicated for the management of inflammatory conditions affecting the eye. Its primary uses include:

  • Post-operative Care: Management of inflammation following surgical procedures, such as cataract surgery.
  • Pain Management: Relief of ocular pain and discomfort associated with corneal epithelial defects or laser surgery.
  • Inhibition of Intraoperative Miosis: Prevention of pupil constriction during ophthalmic surgery to ensure better visibility for the surgeon.
  • General Inflammation: Treatment of non-infectious inflammatory states affecting the anterior segment of the eye.

Physical Characteristics

As an ophthalmic solution, Uniclophen is prepared as a sterile liquid intended for topical administration to the eye. The formulation is designed to provide effective local concentrations of the active ingredient while minimizing systemic absorption.

What side effects are possible with Uniclophen?

Safety Map: Possible side effects and safety information for Uniclophen

Uniclophen (diclofenac sodium ophthalmic solution) is a non-steroidal anti-inflammatory drug (NSAID) administered as eye drops. Its safety profile is documented primarily through adverse reactions related to topical application and known systemic risks associated with NSAIDs.


Adverse reaction scope

Classification Detail (Based on regulatory documents)
Key Adverse Reaction Categories Ocular irritation (application site reactions), Hypersensitivity/Allergic Reactions, and systemic adverse events associated with NSAID use (though less common with topical use).
Frequency Classification Common: Application site reactions (e.g., burning/stinging, pruritus), transient blurred vision immediately after administration. Uncommon/Rare: Hypersensitivity reactions (e.g., rhinitis, urticaria), corneal complications (e.g., thinning, erosion, ulceration, punctate keratitis), especially with frequent dosing or extended treatment.
System-Organ Classes Involved Special Senses (Eye disorders), Skin and Subcutaneous Tissue disorders, and Immune System disorders.
Serious Adverse Reactions Exacerbation of pre-existing corneal disease, development of corneal ulceration or corneal perforation, and potentially fatal systemic anaphylactic reactions in sensitive individuals.
Population-Specific Safety Considerations Contraindicated in the last trimester of pregnancy due to risk of premature closure of the fetal ductus arteriosus. Use with caution during the first and second trimesters and lactation. Contraindicated in children under two years of age.
Dose- or Exposure-Related Patterns Increased risk of corneal adverse events (e.g., erosion, ulceration) reported with prolonged use and/or in patients with compromised corneas.
Safety-Related Restrictions or Limitations Contraindicated for patients with known hypersensitivity to diclofenac, aspirin, or other NSAIDs, particularly those who experience asthma, urticaria, or acute rhinitis following their intake. Must avoid use with soft contact lenses due to the presence of the preservative benzalkonium chloride.

Safety classifications (high-level)

Classification Detail
Regulatory Frequency Framework Used Typically follows general guidelines for adverse event reporting (e.g., by incidence percentage in clinical trials: common 1/100, rare < 1/1000).
Regulatory Basis Derived from governmental regulatory documents pertaining to diclofenac sodium ophthalmic preparations.
Context-of-use Safety Notes Caution is advised in patients prone to bleeding (risk of increased bleeding during surgery). Blurred vision may temporarily impair the ability to drive or operate machinery; wait 15 minutes post-administration before resuming these activities.

Resulting safety structure

Regulatory safety summary:

  • The drug is associated with localized ocular adverse reactions, most commonly transient irritation, immediately following application.
  • It carries serious systemic warnings, characteristic of NSAIDs, regarding hypersensitivity and use near term in pregnancy.
  • The most significant ocular safety risks involve corneal damage (ulceration, perforation), which may occur with intensive or prolonged treatment, particularly in at-risk patients.

Connection to the overall safety profile (2–4 sentences): The official safety information for Uniclophen structures the understanding of risks by separating mild, common local reactions from the rarer but more clinically significant ocular complications like corneal ulceration, and systemic hypersensitivity. This profile emphasizes that while systemic exposure is low, the contraindications for aspirin-sensitive individuals and restrictions during late pregnancy, consistent with other NSAIDs, are critical safety parameters that define the drug's risk management.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Uniclophen (diclofenac sodium ophthalmic solution) defines a low systemic risk for overexposure, reflecting the topical nature of the medicine. The official documentation states that overdosage will not ordinarily cause acute problems.


Overdose Scope and Actions

The management of overdose is specific to the scenario of accidental ingestion of the eye drop solution. The official prescribing information mandates a specific supportive action:

Scenario Required Action (As Labeled)
Accidental Ingestion Fluids should be taken to dilute the medication.

Regulatory Summary

Official labeling does not describe the presence of a specific antidote or require routine hospital monitoring following uncomplicated accidental ingestion. The management is categorized as supportive, focused on the dilution measure. The low-risk classification, where acute problems are not ordinarily expected, is derived from government regulatory assessments of this formulation. Regulatory documents do not contain specific population-based considerations regarding increased severity for pediatric or elderly patients in the overdose section. The sole mandated instruction addresses the specific exposure route of ingestion, defining the action required to mitigate potential non-acute effects.

Therapeutic Uses of Uniclophen

What Uniclophen Treats: Main Uses and Benefits

Uniclophen is commonly used to provide symptomatic relief for symptoms related to inflammatory or irritative states, particularly those involving the front structures of the eye. This topical NSAID is applied across domains where additional symptomatic support is needed. It is relevant in clinical settings for managing the acute pain and swelling that follow ophthalmic procedures, notably cataract extraction and corneal refractive surgery.

The medication is relevant in contexts involving specific inflammatory complications induced by surgery, such as managing the development of cystoid macular edema and addressing pupil constriction (miosis). Furthermore, it is generally used in conditions characterized by periods of heightened symptoms, including allergic conjunctivitis or inflammation resulting from UV radiation exposure or minor non-penetrating injuries. By addressing these symptoms, Uniclophen assists with maintaining functional stability and contributes to improved comfort during symptomatic phases.

“The primary goal is to provide supportive relief when symptoms interfere with routine activities like light sensitivity and discomfort.”


Quick Fact: Supportive Management for Acute Ocular Inflammation The medication is commonly used when symptoms intensify, helping to address pain, swelling, and redness in conditions following surgery or trauma.

Eligibility and Restrictions for Use

Eligibility for Uniclophen (Diclofenac Sodium Ophthalmic Solution)

Official regulatory information defines specific populations that are contraindicated or require special caution when using Uniclophen.

Category Official Regulatory Statement
Populations for whom use is allowed Adult patients who have undergone specific ocular procedures, such as cataract extraction or corneal refractive surgery.
Populations for whom use is contraindicated Patients with known hypersensitivity to diclofenac sodium or any component of the formulation.
Patients in whom asthma, urticaria, or acute rhinitis are precipitated by acetylsalicylic acid (aspirin) or other NSAIDs.
Age-related eligibility rules Pediatric Use: Safety and effectiveness have not been established in patients under 18 years of age.
Condition-specific eligibility rules Use with caution in patients with conditions such as diabetes mellitus, rheumatoid arthritis, or corneal epithelial defects, which may increase the risk of corneal adverse events.
Pregnancy and lactation eligibility status Late Pregnancy: Use must be avoided (contraindicated) from 30 weeks gestation due to potential fetal risk. Lactation: Use is not recommended or advised with caution due to unknown effects on the nursing infant.
Eligibility-related restrictions Use with caution in surgical patients with known bleeding tendencies or those receiving medications that prolong bleeding time.

The official eligibility profile is structured by defining absolute contraindications, such as hypersensitivity and NSAID cross-sensitivity. Eligibility is further constrained by age, as the medicine's safety has not been established in children, and by physiological state, prohibiting use during late pregnancy. Populations with specific corneal risk factors or bleeding tendencies are explicitly advised to use the medicine with caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for Uniclophen (Diclofenac Sodium Ophthalmic Solution) identifies interaction patterns specific to its topical administration and Nonsteroidal Anti-inflammatory Drug (NSAID) classification.

Documented Pharmacodynamic Interactions

The co-administration of topical ophthalmic corticosteroids with Uniclophen is noted in regulatory labels as potentially increasing the risk for corneal healing problems. This is described as a local, additive effect that may slow or delay the natural healing process.

Furthermore, due to the drug’s class effect on thrombocyte aggregation, a theoretical precaution is documented for use alongside medications that prolong bleeding time. This precaution relates to a potential, localized increase in the risk of bleeding in the eye, particularly in the perioperative setting.

Administration Requirements and Systemic Profile

No systemic metabolic interactions, such as those mediated by CYP enzymes or drug transporters, are documented in official regulatory sources, consistent with the minimal systemic absorption of the ophthalmic solution. Additionally, regulatory documents state no known interactions with food or drinks, while the effect of alcohol is officially unknown.

A mandatory timing rule is established for administration: when using other ophthalmic medications, a minimum separation of 5 minutes between applications is required to prevent the active ingredient from being washed out.

Mechanism of Action

Molecular Mechanism: Inhibition of Prostaglandin Synthesis

The fundamental action of Diclofenac is carried out by the inhibition of the Cyclooxygenase (COX) enzymes. Diclofenac acts as a non-selective inhibitor, reversibly blocking the active site of both COX-1 and COX-2 isoforms. . By competitively preventing the binding of arachidonic acid, the compound blocks the initial enzymatic step, resulting in a profound reduction in the local synthesis of prostaglandins and other prostanoids.

Physiological Consequence: Modulation of Nociceptive and Vascular Pathways

The direct physiological consequence of reduced prostaglandin synthesis is the decreased sensitization of peripheral nociceptors and the modulation of local microvascular tone and permeability in the ocular tissues. Prostaglandins sensitize peripheral nociceptors; reducing their concentration lowers the transmission of nociceptive signals. Furthermore, the drug’s mechanism limits prostaglandin-driven vasodilation and increased vascular permeability in the local microvasculature. This mechanism also results in an interference with the physiological pathways governing tissue repair.

Dosage and Administration Information

How to Use Uniclophen

The usage of Uniclophen (diclofenac sodium ophthalmic solution 0.1%) is limited to topical administration to the eye. The medicine is applied directly to the conjunctival sac of the affected eye(s) and must not be injected.

Official Dosing and Frequency

The standard adult dosing regimen involves the instillation of 1 drop per application. The frequency is typically four times daily (QID), with applications spaced throughout waking hours.

Clinical Context Dosage Regimen Course Duration Pattern
Post-Cataract Extraction 1 drop, four times daily (QID) Generally up to two weeks post-surgery.
Post-Refractive Surgery 1 drop, four times daily (QID) Limited to up to three days

Administration and Procedural Rules

Uniclophen is intended only for short-term use to manage acute episodes. The solution is used as supplied with no required dilution. A key procedural rule is the requirement to observe a minimum interval of at least 5 to 15 minutes if other topical eye medications are being used concurrently, which prevents one preparation from washing out another. Additionally, the dropper tip must not contact the eye or any surface to maintain sterility.

Population-Specific Use

Specific dose modifications are generally not required for use in older adults or in patients with hepatic or renal impairment due to minimal systemic exposure. However, the safety and effectiveness of the ophthalmic solution have not been established in pediatric patients (under 18 years).

Recent Clinical Evidence

Research Evidence / Overview of Studies for Uniclophen (Diclofenac Sodium Ophthalmic Solution)

Uniclophen was studied for its evaluation in conditions linked to inflammatory or irritative states of the eye. The available evidence, primarily sourced from major regulatory bodies and peer-reviewed journals, focuses on a few key surgical and traumatic contexts. This research contributes to the broader evidence landscape by describing how the medicine was evaluated in defined patient groups.


Evidence for Use in Managing Inflammation and Pain After Cataract Surgery

Research focusing on post-operative care has typically involved short-term, randomized controlled trials, applied in studies examining patient-reported experiences following surgery. These trials research explored how symptoms evolved in the observed populations, comparing patients who received Uniclophen to those who received a non-active solution (placebo). The main outcomes related to physical discomfort studies explored patient-reported outcomes describing perceived discomfort (ocular pain intensity), and researchers also studies monitored outcomes linked to inflammatory states, such as signs of anterior chamber inflammation (cell and flare scores).

Trials consistently reported measurements where the treated eyes had lower cell and flare scores compared to the placebo group in the immediate post-operative period. Multiple studies reported average pain scores that were lower and less frequent reporting of rescue medication use in the treated population. Data from some trials and meta-analyses reported an association between the medicine and a lower incidence of CME compared to the placebo group. These reported outcomes were short-term and based on the populations studied.

Evidence for Use Following Corneal Refractive Procedures

Randomized controlled trials were applied in research contexts involving fluctuating or unstable symptoms immediately following procedures like Photorefractive Keratectomy (PRK). Research exploring short-term symptom changes was observed in trials with outcomes linked to inflammatory or irritative states. In these acute settings, findings describe patterns observed in the studies where acute pain scores were lower in the treated groups compared to those that received a placebo.

What Research Gaps and Uncertainties Remain

The follow-up durations were limited across many of the key trials, and this remains a consistent research limitation frame for understanding potential long-term effects. Furthermore, while the results apply only to the populations studied, the data for certain groups remain insufficient. For instance, the safety and effectiveness have not been fully established in pediatric patients (under 18 years of age), meaning evidence is limited for this population. In some comparative studies, the findings were mixed regarding patterns observed when research examined Uniclophen alongside other similar anti-inflammatory medicines, indicating that evidence quality varies across studies.

Key Studies & References National Institutes of Health (NIH) - PubMed Central Database

Frequently Asked Questions (FAQ)

Common questions about Uniclophen (FAQ)


Q: How long does it typically take before Uniclophen starts working?

Studies examining the eye solution in clinical trials have looked at symptom relief immediately following procedures. Official data related to pain and light sensitivity relief suggests that effects favored the drug over a non-active solution during the 6-hour period immediately following surgery. This indicates the medicine is designed for a fast, short-term effect.


Q: How long do the effects of Uniclophen usually last?

Uniclophen is an ophthalmic (eye drop) solution designed for local use in the eye, meaning its primary effects are concentrated where it is applied. Regulatory studies tracking the drug’s presence found that levels in the bloodstream were below the limit of detection within four hours. This indicates a very limited systemic (body-wide) duration of the drug.


Q: Is it necessary to take Uniclophen with a full meal, or can it be taken on an empty stomach?

The ophthalmic solution is applied topically to the eye, which results in minimal absorption into the body. Official regulatory documents confirm that there are no known interactions with food or drinks, meaning administration time relative to meals is not a factor for this medicine.


Q: Is Uniclophen generally considered habit-forming or addictive?

No. Uniclophen's active ingredient, diclofenac sodium, is classified as a Non-narcotic analgesic. Regulatory bodies do not list it as a controlled substance, which is the designation for drugs with known abuse potential.


Q: Can Uniclophen cause changes to sleep patterns or cause insomnia?

According to official product information, insomnia (difficulty sleeping) has been reported as an adverse reaction in a small percentage of patients (3% or less) during clinical studies. A healthcare provider is the source for discussing any changes to sleep patterns.


Q: Does Uniclophen affect blood pressure levels?

The systemic absorption of the eye drops is minimal. However, because Uniclophen belongs to the NSAID class, the systemic (oral) forms of this drug are associated with a potential for new or worsening hypertension (high blood pressure). Specific caution for patients with existing blood pressure issues is generally noted due to the drug class association.


Q: Is Uniclophen safe to use during pregnancy, based on official information?

Official regulatory documents state that the drug is contraindicated (must be avoided) starting from 30 weeks gestation due to the risk of fetal harm. Use during the first and second trimesters is described as requiring caution and should only occur if the potential benefit is judged to justify the potential risk.


Q: What are the most commonly reported or high-frequency side effects of Uniclophen?

The most common side effects are those that occur where the medicine is applied. These typically include temporary and localized reactions such as a transient burning or stinging sensation upon instillation, and briefly blurred vision immediately after using the drops.


Q: What common substances or medications are known to interact with Uniclophen?

The primary known interactions are local (within the eye). These include other topical ophthalmic corticosteroids, as the combination may increase the risk of delayed corneal healing. Additionally, there is a theoretical precaution for systemic medications that prolong bleeding time.


Q: What research evidence exists regarding Uniclophen's effectiveness for its stated uses?

Clinical trials consistently reported that the treated eyes showed improvement in signs of inflammation, such as lower cell and flare scores, compared to eyes that received a placebo. Studies also indicated that patients reported lower average pain scores in the short-term period following surgery.


Q: Why is my doctor asking me about my kidney function before prescribing Uniclophen?

Uniclophen is an NSAID. While the eye drop form has minimal systemic absorption, the entire drug class is associated with the potential for renal (kidney) injury with long-term systemic use. Inquiry about kidney health relates to the NSAID class association with potential renal injury, particularly for patients with existing kidney impairment.


Q: Can Uniclophen be taken at the same time as other chronic medications, such as those for diabetes?

Regulatory information indicates that the ophthalmic solution has minimal systemic absorption, meaning it is unlikely to cause typical metabolic interactions. As a result, no systemic metabolic interactions are documented, which is generally favorable when considering use alongside chronic, systemically active medications.


Q: Why do some people experience stomach upset when they take Uniclophen?

Even with minimal systemic absorption, adverse reactions involving the digestive system, such as upset stomach, vomiting, and abdominal pain, were reported in a small percentage of patients in clinical trials. These are characteristic side effects of the NSAID drug class.


Q: Can Uniclophen interact with antidepressants?

Because Uniclophen belongs to the NSAID class, there is a theoretical precaution regarding its use with certain antidepressants like SSRIs and SNRIs. This is because both NSAIDs and these antidepressants can potentially interfere with hemostasis (the body's process to stop bleeding), which may increase the risk of bleeding.


Q: Is Uniclophen used more for inflammation or for pain relief?

The drug is officially indicated for the treatment of both postoperative inflammation and the relief of pain associated with ocular procedures. Clinical trials assessed and demonstrated benefit in treating both pain symptoms and objective measures of inflammation.


Q: What should be done if a user develops a rash after taking Uniclophen?

Regulatory guidelines state that the use of diclofenac should be discontinued at the first appearance of a skin rash or any sign of a hypersensitivity (allergic) reaction. This is a critical safety instruction found in official drug labeling.


Q: Is Uniclophen available in different strengths or formulations?

The product information for the ophthalmic solution (eye drops) specifies that it is supplied as a sterile solution containing 0.1% diclofenac sodium.


Q: Is it normal to feel tired or drowsy after taking Uniclophen?

Drowsiness or unusual tiredness has been reported as a less common side effect in official documents. Furthermore, the blurred vision that commonly occurs immediately after application may temporarily affect the ability to drive.


Q: Are there specific tests a doctor should run before prescribing Uniclophen?

Although the eye drops are not administered long-term, systemic forms of NSAIDs may require monitoring of liver function, blood pressure, and kidney function for extended use. Determining the need for testing is based on professional medical assessment.


Q: Can Uniclophen be used for children or teenagers?

Official product information states that the safety and effectiveness of the eye solution have not been established in pediatric patients (under 18 years of age). Furthermore, the drug is contraindicated for use in children under two years old.


Q: Can Uniclophen cause allergic reactions, and what are the signs?

Yes, the medicine can cause allergic reactions. Reported signs of hypersensitivity include local reactions such as rhinitis (hay fever-like symptoms) and urticaria (hives/itching). Severe systemic reactions like anaphylaxis are rare but possible.


Q: Why are people with liver problems advised to be cautious with Uniclophen?

Diclofenac, as a systemic NSAID, has the potential to cause hepatotoxicity (liver injury). Although the eye drops are minimally absorbed, official documentation mentions monitoring of liver function for patients with existing hepatic impairment.


Q: How long does Uniclophen stay in the body after the last dose?

Studies tracking the systemic presence of the drug found that levels in the bloodstream were below the limit of detection within four hours after the last ocular instillation. This confirms a very rapid clearance from the system following topical application.


Q: Are there any known interactions between Uniclophen and alcohol?

Official regulatory documents state that the specific effect of alcohol on the ophthalmic solution is officially unknown. Specific questions regarding alcohol use should be directed to a healthcare provider.


Q: Can Uniclophen cause dizziness or affect driving ability?

Dizziness has been reported as a less common side effect in clinical studies. Additionally, because a common side effect is temporary blurred vision, regulatory notes advise waiting until vision is clear before driving or operating machinery.


Q: Does Uniclophen have a 'Black Box Warning' in the official labeling?

While the label for the ophthalmic solution does not typically carry a Boxed Warning, systemic forms of diclofenac (oral, injectable) are required to carry one. This warning concerns the potential for serious cardiovascular (heart-related) thrombotic events and serious gastrointestinal complications associated with the entire NSAID class.

How should Uniclophen be stored and disposed of?

Storage and Disposal of Uniclophen (Diclofenac Sodium Ophthalmic Solution)

Uniclophen must be stored according to official regulatory specifications to maintain its quality and sterility.

Required Storage Conditions

The required storage temperature is Controlled Room Temperature (typically 15 C to 30 C or 59 F to 86 F), with an explicit instruction to keep the product from freezing . The medicine must be kept in its original container, tightly closed, and protected from light and moisture.

Stability and Disposal

Once the bottle is opened, the ophthalmic solution must be discarded after 28 days to minimize the risk of contamination. All medicine, whether unused or expired, must be stored out of the sight and reach of children.

Disposal must adhere to local regulations, utilizing authorized drug take-back programs or following specific governmental procedures for safe household trash disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Uniclophen found in:

A-Z Index: